Nasal administration of PLP:OVA-pσ1 prior to PLP_139–151 challenge protects SJL mice from EAE^a.

aSJL mice were challenged s.c. with 200 µg PLP139–151 in complete Freund's adjuvant plus 200 ng PT i.p. on days 0 and 2. bMice were nasally immunized 14 days prior to challenge with 100 µg of PLP:OVA-pσ1 or with PBS. cNumber of mice with EAE/total in group. dMean day ± SD of clinical disease onset. eMaximum (Max.) daily clinical score. fCumulative scores (CS) were calculated as the sum of all scores from disease onset to day 26 post-challenge, divided by the number of mice in each group. * P<0.001 for PBS vs. PLP:OVA-pσ1-dosed mice. gMean score ± SEM of inflammation: the infiltration of nucleated cells into spinal cords was scored from 0 to 4 in each mouse separately, and the mean score and SEM were calculated. *, P<0.001 for PBS vs. PLP:OVA-pσ1-dosed mice. hMean score ± SEM of demyelination: the demyelination in spinal cords was scored from 0 to 4 in each mouse separately, and the mean score and SEM were calculated. *, P<0.001 for PBS vs. PLP:OVA-pσ1-dosed mice.